All In Biotech

Drug Trial Radar · NCT03097796

A Multiple Ascending Dose Study of PUL-042 in Stem Cell Transplant Recipients

An Open-Label, Multiple Ascending Dose Study to Evaluate the Safety and Tolerability of PUL-042 Inhalation Solution in Subjects With Hematologic Malignancies and Recipients of Stem Cell Transplantation

Last checked: Nov 19, 2026Latest source record: Apr 27, 2023 (this record)Source: ClinicalTrials.govMethods & limitations

Withdrawn

Status

Withdrawn

Enrollment

0

Actual

Start

Dec 2024

Primary completion

Mar 2026

Study completion May 2026

Sponsor

Lead sponsor
Pulmotect, Inc.Industry
Sponsor type
Industry
Collaborators
National Heart, Lung, and Blood Institute (NHLBI); Cancer Prevention Research Institute of Texas
First posted
Mar 31, 2017

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Prevention
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Subjects with hematologic malignancies or recipients of a first allogenic or autologus hematopoietic stem cell transplant, without any evidence or respiratory infection, will receive 4 doses of PUL-042 Inhalation Solution over a 2 week period. Subjects will be evaluated for tolerability of the drug. If tolerated, dose escalation may occur with up to 4 dose levels tested

Conditions

  • Hematologic Diseases
  • Stem Cell Transplants

Interventions

  • PUL-042Drug

    PUL-042 Inhalation Solution

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Forced Expiratory Volume in one Second (FEV1)Time frame: 3 weeks

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • University of Texas MD Anderson MD Anderson Cancer Center

    Houston, Texas

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.